WO2023223943A1 - Composition améliorant la fonction de l'endothélium vasculaire - Google Patents

Composition améliorant la fonction de l'endothélium vasculaire Download PDF

Info

Publication number
WO2023223943A1
WO2023223943A1 PCT/JP2023/017828 JP2023017828W WO2023223943A1 WO 2023223943 A1 WO2023223943 A1 WO 2023223943A1 JP 2023017828 W JP2023017828 W JP 2023017828W WO 2023223943 A1 WO2023223943 A1 WO 2023223943A1
Authority
WO
WIPO (PCT)
Prior art keywords
docosahexaenoic acid
compound
sesamin
composition
vascular endothelial
Prior art date
Application number
PCT/JP2023/017828
Other languages
English (en)
Japanese (ja)
Inventor
賢 森田
秀幸 佐々木
Original Assignee
サントリーホールディングス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サントリーホールディングス株式会社 filed Critical サントリーホールディングス株式会社
Publication of WO2023223943A1 publication Critical patent/WO2023223943A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • Vascular endothelial cells are cells that make up the inner surface of blood vessels. Vascular endothelial cells have the function of producing physiologically active substances such as nitric oxide (hereinafter sometimes referred to as NO), and play an important role in maintaining the health of blood vessels.
  • NO physiologically active substances
  • vascular endothelial function vascular endothelial function
  • Certain phospholipids are more preferred, and docosahexaenoic acid, triglycerides in which part or all of the constituent fatty acids are docosahexaenoic acid, and diglycerides in which part or all of the constituent fatty acids are docosahexaenoic acid are more preferred; docosahexaenoic acid, some or all of the constituent fatty acids are Particularly preferred are triglycerides that are all docosahexaenoic acid.
  • the weight of the sesamin compound in terms of sesamin is preferably 2 to 110, more preferably 2.5 to 110, relative to the weight of the docosahexaenoic acid compound in terms of docosahexaenoic acid of 100.
  • the number is more preferably 3 to 109, even more preferably 3.1 to 108.
  • the composition of the present invention can be suitably used to improve vascular endothelial function by reducing intracellular reactive oxygen species in vascular endothelial cells.
  • Lovastatin was added to the medium at a concentration of 10 ⁇ M.
  • Cells cultured in medium supplemented with DMSO served as a control.
  • a medium containing only DHA DHA: 1 ⁇ M
  • SC1 SC1: 1 ⁇ M
  • HUVECs HUVECs were cultured in the same manner as above.
  • DHA, SC1 and lovastatin were dissolved in DMSO and added to the medium.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Husbandry (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention aborde le problème de la fourniture d'une composition améliorant la fonction de l'endothélium vasculaire ayant une action supérieure d'amélioration de la fonction de l'endothélium vasculaire. La présente invention concerne une composition améliorant la fonction de l'endothélium vasculaire qui contient un composé de sésamine et un composé d'acide docosahexaénoïque. Dans la composition : le composé d'acide docosahexaénoïque est au moins un composé choisi dans le groupe constitué par l'acide docosahexaénoïque, des composés comprenant de l'acide docosahexaénoïque en tant qu'acide gras constitutif, et des sels de celui-ci ; et le poids du composé de sésamine exprimé en termes de sésamine est compris entre 2 et 150 lorsque le poids du composé d'acide docosahexaénoïque exprimé en termes d'acide docosahexaénoïque est défini comme étant de 100.
PCT/JP2023/017828 2022-05-16 2023-05-12 Composition améliorant la fonction de l'endothélium vasculaire WO2023223943A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-080069 2022-05-16
JP2022080069 2022-05-16

Publications (1)

Publication Number Publication Date
WO2023223943A1 true WO2023223943A1 (fr) 2023-11-23

Family

ID=88835430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/017828 WO2023223943A1 (fr) 2022-05-16 2023-05-12 Composition améliorant la fonction de l'endothélium vasculaire

Country Status (2)

Country Link
TW (1) TW202402268A (fr)
WO (1) WO2023223943A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06227977A (ja) * 1993-02-01 1994-08-16 Suntory Ltd 活性酸素消去剤
JPH11269456A (ja) * 1998-03-19 1999-10-05 Suntory Ltd 高度不飽和脂肪酸組成物
WO2006016682A1 (fr) * 2004-08-09 2006-02-16 Suntory Limited Agent améliorant pour l'élasticité de vaisseaux sanguins et utilisation de celui-ci
JP2008285463A (ja) * 2007-05-18 2008-11-27 Makiko Funayama 関節症・リウマチ・膠原病の治療薬
WO2015046563A1 (fr) * 2013-09-30 2015-04-02 サントリーホールディングス株式会社 Capsule molle contenant du dha et de l'epa
WO2015093484A1 (fr) * 2013-12-16 2015-06-25 サントリーホールディングス株式会社 Composition à teneur élevée en sésamine
KR101534494B1 (ko) * 2014-01-09 2015-07-07 충남대학교산학협력단 Ｄｈａ를 포함하는 혈관 질환 예방 및 치료용 약학적 조성물
JP2018057329A (ja) * 2016-10-05 2018-04-12 株式会社ディーエイチシー 油脂組成物及びカプセル剤

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06227977A (ja) * 1993-02-01 1994-08-16 Suntory Ltd 活性酸素消去剤
JPH11269456A (ja) * 1998-03-19 1999-10-05 Suntory Ltd 高度不飽和脂肪酸組成物
WO2006016682A1 (fr) * 2004-08-09 2006-02-16 Suntory Limited Agent améliorant pour l'élasticité de vaisseaux sanguins et utilisation de celui-ci
JP2008285463A (ja) * 2007-05-18 2008-11-27 Makiko Funayama 関節症・リウマチ・膠原病の治療薬
WO2015046563A1 (fr) * 2013-09-30 2015-04-02 サントリーホールディングス株式会社 Capsule molle contenant du dha et de l'epa
WO2015093484A1 (fr) * 2013-12-16 2015-06-25 サントリーホールディングス株式会社 Composition à teneur élevée en sésamine
KR101534494B1 (ko) * 2014-01-09 2015-07-07 충남대학교산학협력단 Ｄｈａ를 포함하는 혈관 질환 예방 및 치료용 약학적 조성물
JP2018057329A (ja) * 2016-10-05 2018-04-12 株式会社ディーエイチシー 油脂組成物及びカプセル剤

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
1 January 2004 (2004-01-01), MATSUMURA, YASUO: "Anti-hypertensive effect and vascular endothelial function improvement effect of sesamin", XP009550478 *
ANONYMOUS: "Attention not only men but also women should be careful! "‘Hardness of blood vessels’ is a risk for aging of the whole body!", SUNTORY.CO.JP, 31 August 2017 (2017-08-31), XP093108794, Retrieved from the Internet <URL:https://health.suntory.co.jp/professor/vol17/> [retrieved on 20231205] *
ANONYMOUS: "New release of "active DHA sesamin combination", DYDO.CO.JP, 18 February 2020 (2020-02-18), XP093108780, Retrieved from the Internet <URL:https://www.dydo.co.jp/corporate/news/2020/200218.html> [retrieved on 20231205] *
ANONYMOUS: "New release of "DHA & EPA + Sesamin EX"", SUNTORY.CO.JP, 13 March 2014 (2014-03-13), pages 12005, XP093108776, Retrieved from the Internet <URL:https://www.suntory.co.jp/news/2014/12005.html> [retrieved on 20231205] *
SUNTORY WELLNESS ONLINE: "DHA&EPA+Sesamin EX", SUNTORY WELLNESS - LIST OF HEALTH FOODS AND SUPPLEMENTS - DHA&EPA+SESAMIN EX, XP009550645, Retrieved from the Internet <URL:https://www.suntory-kenko.com/supplement/main/43322_s5811_tst/?utm_referrer=https%3A%2F%2Fwww.suntory-kenko.com%2Fcontents%2F%E2%80%A6> *
YAMAGATA KAZUO: "Docosahexaenoic acid regulates vascular endothelial cell function and prevents cardiovascular disease", LIPIDS IN HEALTH AND DISEASE, BIOMED CENTRAL, LONDON, GB, vol. 16, no. 1, 1 December 2017 (2017-12-01), GB , pages 118, XP093108784, ISSN: 1476-511X, DOI: 10.1186/s12944-017-0514-6 *

Also Published As

Publication number Publication date
TW202402268A (zh) 2024-01-16

Similar Documents

Publication Publication Date Title
CN105050594B (zh) 用于产生升高和持久的酮症的组合物和方法
JP5985138B2 (ja) エネルギー消費促進剤
WO2001087291A1 (fr) Compositions permettant de regulariser le rythme circadien
TW200843726A (en) Agent for relief or prevention of xerostomia
CA2645833C (fr) Compositions contenant de la riboflavine et des sesamines
EP2859896A1 (fr) Compositions pharmaceutiques pour le traitement des troubles musculaires
JPWO2008126367A1 (ja) 精神安定剤および機能性食品
JPH04290822A (ja) アレルギー予防薬および食品
JP2020511434A (ja) ギ酸またはその薬学的に許容可能な塩を有効成分として含む肥満または肥満によって惹起された代謝症候群の予防または治療用組成物
WO2023223943A1 (fr) Composition améliorant la fonction de l&#39;endothélium vasculaire
WO2012036208A1 (fr) Agent d&#39;amélioration de l&#39;oxydation des graisses et du métabolisme énergétique
JP2017137296A (ja) アストロサイトのグルコース代謝活性化剤
CN101208351A (zh) 用于治疗非自体免疫性2型糖尿病和/或x综合征的化合物
WO2021230145A1 (fr) Agent augmentant la concentration de nicotinamide adénine dinucléotide (nad)
WO2021230146A1 (fr) Composition contenant de la sésamine ou similaire et du nr et/ou du nmn
JP2006117687A (ja) 体脂肪の燃焼のための健康食品
JP7344661B2 (ja) 食品組成物の製造方法
JP2020143008A (ja) 新規褐色脂肪細胞分化誘導剤
JP4997514B2 (ja) 血圧上昇抑制剤
JP2000302677A (ja) カルニチン自己産生能改善作用を有する医薬および食品・飼料組成物
KR20140104090A (ko) 커큐민을 유효성분으로 포함하는 지방간 질환의 치료 또는 예방용 조성물
WO2023063230A1 (fr) Composition contenant de la sésamine et de l&#39;ergothionéine ou un sel associé
WO2022071117A1 (fr) Composition anti-fatigue et composition pour améliorer, supprimer la réduction de, et maintenir la performance de production d&#39;énergie
JP6683897B1 (ja) 深部体温低下剤
WO2021065661A1 (fr) Composition de suppression de la baisse de masse musculaire, prévention de la baisse à l&#39;intérieur, son entretien, sa récupération ou son augmentation à l&#39;intérieur

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23807546

Country of ref document: EP

Kind code of ref document: A1